Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on June 11, 2012, to report a material event under Item 8.01 (Other Events). The company is a biopharmaceutical firm focused on the development and commercialization of plant-made pharmaceuticals.
Key Financial Metrics
The filing reports a specific cash inflow event rather than comprehensive financial statements for a period.
- Milestone Payment: $25 million received from Pfizer Inc.
- Trigger Event: U.S. FDA approval of ELELYSO (taliglucerase alfa) for type 1 Gaucher disease on May 1, 2012.
- Agreement Context: Payment is part of a global commercial agreement with Pfizer.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, margins, total debt, or overall liquidity positions for the reporting period.
Material Changes
The primary material change is the receipt of the $25 million milestone payment, which represents a significant non-recurring cash inflow tied to regulatory approval. This event marks a transition from development to commercialization for the ELELYSO product in the United States.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the FDA approval and the subsequent milestone payment. The filing does not contain forward-looking guidance, updated financial outlooks, or a discussion of specific risks and contingencies beyond the context of the commercial agreement.
Investor Verification Checklist
- Verify the terms of the global commercial agreement with Pfizer to understand future milestone and royalty obligations.
- Confirm the impact of the $25 million payment on the company's current cash position and runway.
- Review the FDA approval letter for ELELYSO to ensure no restrictive conditions were attached to the May 1, 2012 approval.
- Check subsequent filings for the actual cash balance and any changes in debt levels following this transaction.